MSLN and ovarian carcinoma: The high expression of MSLN was also significantly correlated with the decrease of overall survival at different clinical stages of ovarian cancer (Stage 1, p=0.13; Stage 2, p=0.14; Stage 3, p=0.02; Stage 4, p=0.001) (Figures 3, D−G).